Measles virus vaccine, live Subcutaneous and Stelazine

• Generic Name: measles virus vaccine
• Dosage Forms: n.a.
• Other Brand Names:

Measles Virus Vaccine Live is an immunizing agent used to prevent infection by the measles virus. It works by causing your body to produce its own protection (antibodies) against the virus. This vaccine does not protect you against German measles (Rubella). A separate immunization is needed for that type of measles.

Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and ten-day measles) is an infection that is easily spread from one person to another. Infection with measles can lead to serious problems, such as pneumonia, ear infections, sinus problems, convulsions (seizures), brain damage, and possibly death. The risk of serious complications and death is greater for adults and infants than for children and teenagers.

Immunization against measles is recommended for everyone 12 to 15 months of age and older. In addition, there may be special reasons why children from 6 months of age up to 12 months of age may also require measles vaccine.

Immunization against measles is usually not recommended for infants up to 12 months of age, unless the risk of their getting a measles infection is high. This is because antibodies they received from their mothers before birth may interfere with the effectiveness of the vaccine. Children who were immunized against measles before 12 months of age should be immunized twice again.

You can be considered to be immune to measles only if you received two doses of measles vaccine starting on or after your first birthday and have the medical record to prove it, if you have a doctor's diagnosis of a previous measles infection, or if you have had a blood test showing immunity to measles.

This vaccine is to be administered only by or under the supervision of your doctor or other health care professional.

• Generic Name: trifluoperazine
• Dosage Forms: n.a.
• Other Brand Names: Stelazine

Treatment of schizophrenia.

American Psychiatric Association (APA) considers most atypical antipsychotic agents first-line drugs for management of the acute phase of schizophrenia (including first psychotic episodes). APA considers conventional antipsychotic agents first-line in patients with acute psychotic episodes who have been treated successfully in the past with, or who prefer, conventional agents.

Patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.

Short-term management of nonpsychotic anxiety in patients with generalized anxiety disorder.

Not established whether trifluoperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Efficacy not established for the management of behavioral complications in patients with mental retardation.